Trial record 10 of 35 for:    Open Studies | "Celiac Disease"

Celiac Disease Genomic Environmental Microbiome and Metabolomic Study (CDGEMM)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Massachusetts General Hospital
Sponsor:
Collaborators:
University of Roma La Sapienza
Università Politecnica delle Marche
Information provided by (Responsible Party):
Alessio Fasano, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT02061306
First received: February 6, 2014
Last updated: March 14, 2014
Last verified: March 2014
  Purpose

Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of these factors as possible and study how they each contribute to disease development. If the investigators find that any one factor, or combination of factors, increases the risk of developing CD, we will be able to apply this information and help prevent or detect disease in high-risk children in the future.


Condition
Celiac Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) Study

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Change in composition of the microbiota of CD in at-risk infants using culture-independent high-throughput sequence analysis of the 16S rRNA genes using the Illumina sequencing platform. [ Time Frame: Every six months through five years of age with specific focus on time of gluten introduction, time at which gluten tolerance is lost and autoimmunity develops (if applicable), and parallel time points in infants who do not go on to develop autoimmunity ] [ Designated as safety issue: No ]
    We will use stool samples collected over time to survey the microbial community in order to establish microbiota patterns associated with CD autoimmunity.


Secondary Outcome Measures:
  • Change in gut permeability measured by serum zonulin levels and loss of gluten tolerance measured by increased expression of pro-inflammatory cytokines and appearance of anti-tTg antibodies. [ Time Frame: Every six months until age 3. Every year thereafter until age 5. ] [ Designated as safety issue: No ]
    We anticipate that timing of gluten introduction in the infant's diet will influence shift in enterotype and metatranscriptome profile with subsequent increase in gut permeability and loss of gluten tolerance.


Other Outcome Measures:
  • Comparison of the characterization of infants' metabotypes (metabolomes) using an established and proven commercial metabolomics technology platform by Metabolon, Inc. [ Time Frame: Every six months through five years of age with specific focus on time of gluten introduction, time at which gluten tolerance is lost and autoimmunity develops (if applicable), and parallel time points in infants who do not go on to develop autoimmunity ] [ Designated as safety issue: No ]
    Our preliminary data suggest that individual metabolomic phenotypes (which are a result of gene-diet-gut microbiome interactions) can help define specific enterotypes associated to loss of gluten tolerance in infants genetically at risk of CD.


Biospecimen Retention:   Samples With DNA

Infant stool and whole blood samples. Maternal stool and breast milk samples.


Estimated Enrollment: 400
Study Start Date: March 2014
Estimated Study Completion Date: December 2024
Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)
Groups/Cohorts
Infants with a first-degree relative with celiac disease
Infants who have not been introduced to solid food and have a relative with biopsy proven celiac disease.

Detailed Description:

The CDGEMM study will address genomic, environmental, microbiome, and metabolomic factors that could affect the development of CD.

Genomic: The investigators will study children who have a first degree relative with celiac disease so that we can understand how their genes may contribute to whether they develop CD or not. Scientists and doctors are already aware of one group of genes, called the HLA DQ2 and DQ8 genes, which are involved in the development of CD. These genes are necessary for development of CD, but cannot alone predict who will develop the disease. The investigators hope that the CDGEMM study will help to not only learn more about these specific genes, but also identify other genes that could make it easier to predict who will develop CD.

Environmental: When infants enroll, the investigators will record information about their environment including whether they were born vaginally or by Cesarean section and whether they were given antibiotics. Over time, the investigators will also consider other parts of the infant's medical history including feeding modality (breastfeeding versus formula feeding), illnesses, infections, and growth to understand if any of this information is related to CD development. Since the investigators will follow infants until they reach 5 years of age, the investigators will update this information every six months to understand how changes might affect if the child develops CD or not.

Microbiome: Our gut, compromised of the small and large intestine, contains many types of bacteria. These bacteria that live in the gut normally help to break down and digest food, provide our bodies with energy, and make vitamins that our bodies need. This diverse community of bacteria is called the gut microbiome. A main goal of the CDGEMM study is to understand how the microbiome is affected by other factors, like foods or antibiotic drugs, and how this may affect the development of CD. It is possible that learning about the types of bacteria living in the gut before and after disease development may help us predict who will develop CD before it happens.

Metabolomic: The processes that occur in our gut, such as the digestion of foods and production of vitamins, create products that are called metabolites. The specific metabolites that we produce differ from person to person and depend on many factors, including the genes that we have, the members of the gut microbiome, and the foods that we eat. We will study the infant's unique metabolomic profile (metabolites that the infant produces) to understand if there is a specific profile associated with CD.

  Eligibility

Ages Eligible for Study:   up to 6 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Newborns and infants younger than 6 months who are first-degree relatives of CD patients (at least one parent or sibling affected with biopsy-proven CD) are eligible for participation.

Criteria

Inclusion Criteria:

  • Newborns and infants less than 6 months of age who have not been introduced to solid foods (exclusive breast milk or formula diet)
  • First-degree relatives of patients affected with biopsy-proven CD

Exclusion Criteria:

  • Infants older than 6 months of age
  • Inability or unwillingness of legal guardian/representative to give written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02061306

Locations
United States, Massachusetts
Massachusetts General Hospital for Children Recruiting
Boston, Massachusetts, United States, 02114
Contact: Stephanie Camhi    617-643-9942    sscamhi@mgh.harvard.edu   
Principal Investigator: Alessio Fasano, MD         
Sub-Investigator: Maureen M. Leonard, MD         
Italy
Università Politecnica delle Marche Not yet recruiting
Ancona, Italy, 60123
Contact: Carlo Catassi, MD MPH    0033-071-596-2364    catassi@tin.it   
Principal Investigator: Carlo Catassi, MD MPH         
University of Roma La Sapienza Not yet recruiting
Rome, Italy, 00185
Contact: Francesco Valitutti       francesco.valitutti@uniroma1.it   
Principal Investigator: Salvatore Cucchiara, MD PhD         
Sponsors and Collaborators
Massachusetts General Hospital
University of Roma La Sapienza
Università Politecnica delle Marche
Investigators
Principal Investigator: Alessio Fasano, MD Massachusetts General Hospital
Study Chair: Maureen M. Leonard, MD Massachusetts General Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: Alessio Fasano, Chief of Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT02061306     History of Changes
Other Study ID Numbers: 2013P001965
Study First Received: February 6, 2014
Last Updated: March 14, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Celiac disease, microbiome, gluten, infants, pregnancy, genetic, metabolomic

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on July 23, 2014